Amylyx Pharmaceuticals, Inc.

US$29.50As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:AMLXHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR 5.19%
Div yield —
ROE (30.06%)
Drug Manufacturers (Specialty & Generic)
Beta (5Y) (0.08)
PE TTM —
TSR TTM 111.77%
Mkt cap US$3.793B
ROIC (20.03%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$30
2.31%
(91.93%)
Hold 2|5|9|9|2
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.38
0.36
0.35
0.37
12.64%
(1.50%)
(0.47%)
8.46%
Revenue$M
301.1
294.3
299.6
297.9
8.68%
4.09%
1.48%
(0.51%)
Peers (US$3.793B)
Cap (US$)
PE
5.434B
7.363x
3.974B
30.04x
2.777B
—
3.738B
6.110x
Capital
TTM
5Y
10Y
Leveragex
0.126
0.053
0.042
EBIT/Intx
0.334
0.099
0.126
Own earn%
33.80
3.47
0.20
Sh yield%
32.53
48.87
45.61
Owners
Insiders/Inst%
0.71
64.98
Short interest%
3.83
SBC / revenue%
0.64
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
1
Op margin range%
7–12
$1 testx
—
Incr. ROIC%
2